Rezolute to participate in the guggenheim smid cap biotech conference

Redwood city, calif., jan. 31, 2025 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the guggenheim smid cap biotech conference, taking place february 5-6, 2025, in new york city.
RZLT Ratings Summary
RZLT Quant Ranking